A phase II trial on [177Lu]Lu-PSMA in heavily pretreated progressive prostate cancer showed efficacy, i.e., a PSA decline > 50%, in 57% of patients and a progression-free survival of 7.6 months [13]. Here, FOLH1 is linked to prostate carcinoma.